ViiV Healthcare’s Long-Acting HIV Treatment Cabenuva Meets Primary Endpoint of Superior Viral Suppression

ViiV Healthcare's Cabenuva Achieves Superior Viral Suppression in Viremic HIV Patients

ViiV Healthcare announced that its Phase IIIb CROWN study, evaluating the long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine), met its primary endpoint. At six months, Cabenuva demonstrated superior rates of viral suppression compared to standard-of-care oral antiretroviral therapy in approximately 326 adults and adolescents living with HIV-1 who had detectable virus at study entry. This international, randomised, open-label trial is the first large study to assess direct initiation of long-acting Cabenuva in treatment-experienced individuals with unsuppressed HIV, addressing a significant evidence gap. The results build on previous data and will be shared with health authorities for regulatory review.

• The CROWN study successfully demonstrated that ViiV Healthcare's long-acting Cabenuva (cabotegravir + rilpivirine) achieved superior rates of viral suppression at six months compared to daily oral antiretroviral therapy. This outcome was observed in adults and adolescents living with HIV-1 who had detectable virus at the start of the study, highlighting the potential of this regimen for a challenging patient population.
• CROWN is the first large, international Phase IIIb trial to investigate the direct initiation of long-acting Cabenuva in people with a history of antiretroviral treatment and unsuppressed HIV (viremia). This study specifically addresses a critical evidence gap by evaluating the regimen in individuals who had detectable virus at study entry and no known resistance to INSTIs or NNRTIs, expanding the understanding of its utility beyond virologically suppressed patients.
• While Cabenuva is approved for virologically suppressed patients, its use in people with detectable viremia remains investigational and is not yet approved by regulatory authorities. ViiV Healthcare plans to share the full results from the CROWN study, which enrolled approximately 326 participants across eight countries, with health authorities for regulatory review, with full data presentation anticipated at an upcoming scientific meeting.

Addressing Unmet Needs in HIV-1 Viremia Management

We are experiencing a brief delay in retrieving the requested information. Please retry after a short interval. Ensuring the accuracy of information remains our top priority.

CROWN: Superior Viral Suppression with Long-Acting Cabenuva

We are experiencing a brief delay in retrieving the requested information. Please retry after a short interval. Ensuring the accuracy of information remains our top priority.

Long-Acting Cabenuva: Reshaping the HIV Treatment Landscape

We are experiencing a brief delay in retrieving the requested information. Please retry after a short interval. Ensuring the accuracy of information remains our top priority.

Expanding Cabenuva's Reach in Challenging HIV Cases

The recent announcement from ViiV Healthcare regarding its Phase IIIb CROWN study represents a pivotal moment for the long-acting HIV treatment landscape. Cabenuva, an established injectable regimen, has demonstrated superior viral suppression in a patient population that has historically presented significant challenges: individuals who are treatment-experienced and living with unsuppressed HIV. This is not merely an incremental gain; it addresses a critical evidence gap by showing that direct initiation of a long-acting therapy can be effective in those who have struggled to achieve viral control with daily oral regimens.

For ViiV Healthcare, this success translates into substantial strategic implications. It significantly expands the addressable market for Cabenuva, moving beyond its current use in virally suppressed patients to encompass a new, underserved segment. This differentiation reinforces ViiV's leadership in long-acting HIV therapies, potentially setting a new standard of care and extending the drug's lifecycle. A successful regulatory review could lead to a crucial label expansion, streamlining treatment pathways and accelerating uptake in clinical practice by offering a simplified, effective option for a complex patient group.

However, as with any significant therapeutic advancement, certain risks warrant careful consideration. While Cabenuva's overall safety profile is known, its long-term tolerability and safety in this specific population—those with detectable virus and potentially underlying resistance—will require ongoing scrutiny. Furthermore, while long-acting injectables aim to improve adherence, ensuring consistent patient follow-up for scheduled injections, particularly in a population that may have struggled with oral adherence, remains a practical implementation challenge. There is also an inherent risk of resistance development if adherence to the injection schedule is suboptimal, which could compromise future treatment options for these vulnerable individuals.

Ultimately, the CROWN study's findings suggest a potential paradigm shift, offering a new pathway for managing HIV-1 in patients who have not achieved viral suppression. This could lead to improved patient outcomes, reduced pill burden, and a more robust toolkit for clinicians tackling the complexities of HIV management, particularly in settings where adherence to daily oral medication is a persistent barrier. The forthcoming regulatory submissions will be closely watched, as they could unlock a new era for long-acting HIV treatment.